Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 29 articles: HTML format

Single Articles

November 2025
1. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
   Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
   Vaccine. 2025;69:127973.
   PubMed    
   
   
   
2. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
   Value profile for Malaria vaccines and monoclonal antibodies.
   Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
   PubMed     Abstract available
   
   
   
3. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
   Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.
   Vaccine. 2025;68:127897.
   PubMed     Abstract available
   
   
   October 2025
4. ANOSIKE C, Ojiakor IM, Etiaba EI, Uguru NP, et al
   Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
   Vaccine. 2025;67:127853.
   PubMed     Abstract available
   
   
   
5. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
   Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
   Vaccine. 2025;66:127832.
   PubMed     Abstract available
   
   
   September 2025
6. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
   Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
   Vaccine. 2025;63:127673.
   PubMed     Abstract available
   
   
   July 2025
7. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
   Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
   Vaccine. 2025;60:127323.
   PubMed     Abstract available
   
   
   June 2025
8. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
   Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
   Vaccine. 2025;61:127376.
   PubMed     Abstract available
   
   
   May 2025
9. YUN SY, Nguyen MN, Hong H, Bae GJ, et al
   Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii.
   Vaccine. 2025;55:127032.
   PubMed     Abstract available
   
   
   April 2025
10. PARVEEN S, Rath PP, Tabrez S, Khan S, et al
    Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
    Vaccine. 2025;54:126993.
    PubMed     Abstract available
    
    
    
11. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    PubMed     Abstract available
    
    
    
12. DESHMUKH B, Khatri D, Kochar SK, Athale C, et al
    In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.
    Vaccine. 2025;53:126952.
    PubMed     Abstract available
    
    
    
13. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    PubMed     Abstract available
    
    
    February 2025
14. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    PubMed     Abstract available
    
    
    January 2025
15. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    PubMed     Abstract available
    
    
    October 2024
16. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    PubMed     Abstract available
    
    
    July 2024
17. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    PubMed     Abstract available
    
    
    
18. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    May 2024
19. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
20. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    April 2024
21. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    March 2024
22. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    February 2024
23. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
24. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    November 2023
25. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    
26. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    PubMed     Abstract available
    
    
    August 2023
27. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    May 2023
28. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    PubMed     Abstract available
    
    
    April 2023
29. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malaria is free of charge.